Molnupiravir | CAS 2492423-29-5 | USP/EP-Certified Antiviral API for COVID-19 Treatment
Google Keywords: Molnupiravir bulk supplier, antiviral API for COVID-19, USP/EP-certified Molnupiravir, RNA mutagen drug
🌟 Product Overview
Molnupiravir (CAS 2492423-29-5) is a broad-spectrum antiviral nucleoside analog approved for the treatment of mild-to-moderate COVID-19. It acts by inducing RNA mutagenesis in viral replication, effectively reducing viral load and transmission12. Widely used in clinical and research settings, it is formulated as a white crystalline powder for oral administration14.
✔️ Key Advantages
High Purity: ≥98% HPLC purity compliant with USP/EP standards, ensuring pharmaceutical-grade quality12.
Bulk Customization: Available in 1g–25kg batches with COA, MSDS, and stability data for seamless integration into drug formulations12.
Solubility: Optimized for DMSO solubility (≥20 mg/mL) to support preclinical and clinical studies36.
🏥 Applications
COVID-19 Therapy: First-line oral treatment for reducing symptom severity and hospitalization rates13.
Antiviral Drug Development: Key reference standard for RNA virus-targeted drug discovery24.
Research: Mechanistic studies on viral mutagenesis and resistance profiling35.
📜 Quality Compliance
Certified under USP/EP guidelines with residual solvents <10 ppm and heavy metals <20 ppm25.
Stability tested for 24 months when stored at -20°C in airtight, light-protected packaging24.
📈 Market Trends
The global antiviral drug market is projected to grow at 7.8% CAGR (2025-2030), driven by persistent demand for COVID-19 therapeutics. Molnupiravir’s oral bioavailability and rapid action solidify its role in pandemic preparedness13.
China
